Program
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203
Its studies are mostly in Lymphoma, Large B-Cell, Diffuse, led by AvenCell Therapeutics.
Furthest: phase 2, since Nov 25, 20251 company-led study, 1 open or runningNext primary completion: Apr 27, 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AvenCell Therapeutics | 11 open or running | phase 2since Nov 25, 2025 | Nov 25, 2025 | Apr 27, 2029phase 2 · NCT07284433 |
Also a collaborator on its studies: AvenCell Europe.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 25, 2025First study: phase 2 study in Lymphoma, Large B-Cell, DiffuseFirst studyNCT07284433 · 178 planned · United States, Germany
Ahead
- Apr 27, 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07284433
TargetBeta
“An off-the-shelf (OTS) preparation of human allogeneic T-lymphocytes genetically modified to express a chimeric antigen receptor (CAR) specific for both the tumor-associated antigen (TAA) CD19 and the TAA CD20, and clustered regularly interspaced short palindromic repeats (”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
| Autologous Anti-CD19/CD20 CAR-T Cells KITE-363rule | Gilead Sciences | phase 2 | 3 |
| prizloncabtagene autoleucelrule | AbelZeta | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| CT204V-CD19 × CD20rule | AstraZeneca | phase 2 | 1 |
| HB2198rule | hinge-bio | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07284433Lymphoma, Large B-Cell, Diffuse · United States, Germany | 2 | Recruiting | Apr 27, 2029 | 178 |
How it is read
Names in the registry
- “Allo-QuadCAR01-T”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.